Market closed·Syncing…
Market closed · Close · 18 Nov

AstraZeneca Pharma India Limited ASTRAZENshare price and chart

AstraZeneca Pharma India closed at ₹6,043.50 on 18 November 2026, down 2.02% on the day. The 52-week range is ₹5,640.00 to ₹9,469.50.

₹6,043.50The price one share last traded at, in rupees.▼ 2.02% · ₹124.60
52-wk low ₹5,64011% up the rangeThe highest and lowest price the share has traded at in the past year, and where today's price sits between the two.high ₹9,470

Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.

Loading prices…

Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.

Test a strategy on ASTRAZEN

Real prices, every charge counted. Pick one or write your own.
What AstraZeneca Pharma India Limited does
A short, human-reviewed summary of the business, written from public sources. Background, not analysis, and not updated intraday.
business summary

AstraZeneca Pharma India, the Indian listed arm of AstraZeneca, markets and sells medicines in India, with marketing and trading 90% of its turnover. Its customers are distributors, hospitals and government institutions. It was incorporated in 1979 and is based in Bengaluru.

1
1Sector

Pharmaceuticals & Biotechnology

2
2What it sells

Prescription medicines

3
3Who buys it

Distributors, hospitals, government institutions

Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.

EOD 18 Nov
RSI (14) · 30 oversold, 70 overboughtA score from 0 to 100 showing how strong recent up days were against recent down days.
40.8Neutral
0 oversold3070overbought 100
Delivery · bought to hold vs churnOf all the shares traded in a day, the share that actually changed hands and went into someone's demat account, rather than being bought and sold the same day.
35.5%Near average
today 35.5%20d avg 48.2%

The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.

vs 50 DMAHow far today's close is above or below the average closing price of the last 50 trading days. It shows the medium-term trend.▼ 4.1%vs 200 DMAHow far today's close is above or below the average closing price of the last 200 trading days, about ten months. It is the most watched line for the long-term trend.▼ 22.4%1 monthHow much the share price has changed over the period.+0.1%3 monthsHow much the share price has changed over the period.▼ 20.9%1 yearHow much the share price has changed over the period.▼ 34.9%Vol 30dHow much the share has actually been moving day to day, stated as a yearly percentage. 30% means it swung roughly 30% a year at that pace.29.2%

Returns and valuationWhat the market pays for this company and how well the business uses its money.

Books to 30 Sept 2026
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.₹15,109 Cr18 NovP/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.85.0xlast 4 quarters, to Sept 2026Return on equityHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.22.8%full year FY26Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.17.19xbooks of Sept 2026Return on capitalHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.31.2%full year FY26EV / EBITDAWhat it would cost to buy the whole company, against the cash profit its business makes in a year. It is a P/E that ignores how the company is financed.51.0xDividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.0.60%last 12 monthsDebt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.00xbooks of Sept 2026FCF marginOf every ₹100 of sales, how much cash was left after running the business and paying for new assets.-0.8%year to Mar 2026

Against its sectorWhere this company ranks among similar companies on each measure.

Pharmaceuticals · 141 peers · medians
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.85.01vs 32.7 median
Cheapest: WALPAR 7.92Priciest: COHANCE 507.11
Net marginOf every ₹100 of sales, how much is left as profit after all costs, interest and tax.6.83%vs 10.23% median
Lowest: MEDIORG -86.72%Highest: SHUKRAPHAR 38.89%
Revenue growthHow much sales grew in the latest quarter against the same quarter a year earlier.30.41%vs 20.87% median
Lowest: NECLIFE -99.78%Highest: SHUKRAPHAR 652.15%

What the numbers sayShort plain statements about this company's latest figures.

Written by fixed rules

Latest quarterIn the quarter to September 2026 (results filed 5 Nov 2026), sales rose 30.4% from a year earlier to ₹729 cr and profit rose 15.0% to ₹62.3 cr.

Going well
  • Sales grew 4 years running (₹806 cr in FY22 to ₹2,276 cr in FY26).
  • Return on equity stayed above 15% from FY24 to FY26 (lowest 15.6%).
  • No borrowings at the FY26 balance sheet.
  • No promoter shares were pledged at the end of June 2026.
Worth watching
  • Operating margin fell from 16.5% in FY23 to 11.5% in FY26.
  • Operations used cash in FY26 (-₹15.1 cr) while reported profit was ₹188 cr.

Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.

Share price reaction to resultsWhat the share price did around each recent quarterly result.

Over the last 20 results, the share rose on 6 and fell on 14, and moved by 3% or more on 7.

+18%
-18%
Q2 FY23Q2 FY24Q2 FY25Q2 FY26Q2 FY27

Q2 FY27: results filed 5 Nov 2026. The share went from its close on 4 Nov 2026 to its close on 6 Nov 2026 +0.09%.

Dividend historyCash the company has paid per share, year by year.

₹600 / year
Paid 8 of 8 yrs
on ₹1 lakh at today's price · 0.60% yield · ₹36/share
What each year paid, on ₹1 lakh
17
33
33
132
265
397
529
596
19
20
21
22
23
24
25
26*
* 2026 so far - more may still be declared this year

2026 has paid ₹36.00 per share, about ₹596 on ₹1 lakh at today's price. Dividends are at the company's discretion and can be cut or skipped.

What it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.

Price only, before dividends
+20.5%a year, over 10 years
1 yr
-33.0%
3 yr
+9.4%
5 yr
+14.6%
10 yr
+20.5%

Held for 10 years this compounded at +20.5% a year. The last twelve months were down -33.0%. Price only, before dividends.

Shareholding patternThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.

Who owns it
75%promoter holding, as of 2026-09-30+0.0 pts since 2021
Promoter share since listing
2021-0975% now, drawn to its own range2026-09
Who owns it todayas of Sep 26
75.0%
15.3%
Promoter75.0%Foreign (FII)2.6%Domestic (DII)7.1%Public & others15.3%
Who is buying, who is leavingJun 25 to Sep 26
Promoter75.0%steady
Foreign (FII)2.6%-0.4 pts
Domestic (DII)7.1%+2.5 pts

Each line is that holder's share of all shares over the last 6 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.

The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.

Promoter pledgeThe share of promoters' holdings given to lenders as security for a loan.0.00%of promoter shares, as at 2026-06-30

Recent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.

Last 6 months
Updates17-Nov-2026

AstraZeneca Pharma India Limited has informed the Exchange regarding 'Revised submission with functional link - Letter of Intent with Strand Life Sciences Private Limited - Disclosure of LinkedIn Communication'.

Updates17-Nov-2026

AstraZeneca Pharma India Limited has informed the Exchange regarding 'Letter of Intent with Strand Life Sciences Private Limited - Disclosure of LinkedIn Communication'.

Shareholders meeting17-Nov-2026

AstraZeneca Pharma India Limited has informed the Exchange regarding Notice of Postal Ballot

Product launch07-Nov-2026

AstraZeneca Pharma India Limited has informed the Exchange about Product launch

General Updates05-Nov-2026

AstraZeneca Pharma India Limited has informed the Exchange about General Updates

Press Release05-Nov-2026

AstraZeneca Pharma India Limited has informed the Exchange regarding a press release dated November 05, 2026, titled "Press Release".

General Updates05-Nov-2026

AstraZeneca Pharma India Limited has informed the Exchange about General Updates

General Updates05-Nov-2026

AstraZeneca Pharma India Limited has informed the Exchange about Appointment/ Change in designation of Senior Management Personnel

General Updates05-Nov-2026

AstraZeneca Pharma India Limited has informed the Exchange about Appointment of Chief Financial Officer

Outcome of Board Meeting05-Nov-2026

AstraZeneca Pharma India Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

General Updates02-Nov-2026

AstraZeneca Pharma India Limited has informed the Exchange about General Updates

Certificate under SEBI (Depositories and Participants) Regulations, 201827-Oct-2026

AstraZeneca Pharma India Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

Press Release16-Oct-2026

AstraZeneca Pharma India Limited has informed the Exchange regarding a press release dated October 16, 2026, titled "AstraZeneca Pharma India announces new Mumbai corporate office, marking the next phase of growth through innovation".

Shareholders meeting16-Oct-2026

AstraZeneca Pharma India Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.

Credit Rating- New16-Oct-2026

AstraZeneca Pharma India Limited has informed the Exchange about Credit Rating- New

Backtest idea · ASTRAZENMACD momentum

Momentum turning up, only while the long trend is up.

BuyMACD crosses above signal, price above 200-day SMA
SellMACD crosses back below
Real prices · every charge countedRun on ASTRAZEN
Backtest idea · ASTRAZENLower band bounce

Buys a stretch below the usual range, sells on the way back.

BuyCloses below the lower Bollinger band
SellBack at the middle band, or 15 days
Real prices · every charge countedRun on ASTRAZEN
Backtest idea · ASTRAZENSupertrend rider

Stays in while the trend line says up, out when it flips.

BuySupertrend turns up
SellSupertrend turns down
Real prices · every charge countedRun on ASTRAZEN
Your own ideaWrite a rule for ASTRAZEN in plain English“Buy ASTRAZEN when …”
Start writing
Buy the dip on ASTRAZENBuy when RSI(14) drops below 30
52-week high breakout on ASTRAZENBuy when closes at a 52-week high
Golden cross on ASTRAZENBuy when 50-day EMA crosses above 200-day
Stochastic oversold on ASTRAZENBuy when stochastic %K drops below 20
Pullback in an uptrend on ASTRAZENBuy when RSI(14) below 40, price above 200-day EMA

Key ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.

Against its sector
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.
₹15,109 cr
Larger than 75% of 141 peers
sector middle ₹2,247 cr
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.
85.0x
Higher than 92% of 118 peers
sector middle 32.7x
Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.
17.2x
Higher than 95% of 125 peers
sector middle 3.6x
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.
22.8%
Higher than 89% of 109 peers
sector middle 12.3%
FY23 16.9%FY26 22.8%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.
31.2%
Higher than 92% of 124 peers
sector middle 14.9%
FY23 22.9%FY26 31.2%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.
0.00
No borrowings
sector middle 0.19
FY23 0.00FY26 0.00
Dividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
0.6%
Higher than 80% of 141 peers
sector middle 0.1%
Sales growthHow much sales grew in the latest quarter against the same quarter a year earlier.
+30.4%
Higher than 65% of 130 peers
sector middle +20.9%
FY23 24.5%FY26 32.6%

Peers are the listed companies in the exchange's own industry group: Pharmaceuticals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.

Revenue and profit, year by yearSales and net profit by financial year or by quarter.

Sales and net profit
FY22FY23FY24FY25FY26
SalesNet profitfell vs last yearEach on its own scale · hover a bar for its figures
Op. marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.11.5%FY26Profit YoYHow much net profit grew in the latest quarter against the same quarter a year earlier.+15.0%latest quarterSalesMoney earned from selling the company's goods and services, before any costs. Also called revenue.₹2,276 CrFY26Net profitWhat is left for shareholders after all costs, interest and tax.₹188 CrFY26

Where every ₹100 of sales goesHow each ₹100 the company sold was spent, and how much stayed as profit.

FY26

In FY26, of every ₹100 of sales it kept ₹8.2 as profit. Other income added ₹1.3.

Where it wentPer ₹100 of sales
Running costs₹88.5Depreciation₹1.3Interest₹0.2Tax₹2.8Profit₹8.2
Profit per ₹100, year by year
FY22FY26

How fast it has grownCompound growth a year in sales and profit, over 3 and 5 financial years, beside the latest quarter.

Compounded a year
3 years5 yearsLatest qtr
Sales+31.4%-+30.4%
Profit+23.6%-+15.0%
3 and 5 years are compounded a year across full financial years. The latest quarter is against the same quarter a year earlier.

Cash flowProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.

Where the cash went

In FY26 cash fell by ₹88 Cr, after ₹4 Cr spent on plant and equipment.

FY26Cash in or out
Running the business-₹15 Cr
Investing+₹19 Cr
Lenders and shareholders-₹92 Cr
Net change in cash-₹88 Cr
Operating cash per ₹100 of profit
₹59FY23₹57FY24₹56FY25₹-8FY26
₹100 or more means the reported profit arrived as cash.

Health check, year by yearMargins, returns and debt for each financial year, so you can see the direction.

MeasureFY23FY24FY25FY26
Sales growthSales in this financial year against the previous one.24.5%29.2%32.5%32.6%
Operating marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.16.5%14.2%14.8%11.5%
Net marginOf every ₹100 of sales in the year, how much was left as profit after everything.9.9%12.5%6.7%8.2%
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.16.9%24.8%15.6%22.8%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.22.9%33.9%21.3%31.2%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.00x0.00x0.00x0.00x
Interest coverHow many times the company's profit before interest could pay its interest bill.225x184x105x57.0x

Each row against this company's own usual level: green better, red worse, grey close to it.

Backtest idea · ASTRAZENStochastic oversold

Buys when the close sits near the bottom of its recent range.

BuyStochastic %K drops below 20
Sell8% profit, or after 15 days
Real prices · every charge countedRun on ASTRAZEN
Backtest idea · ASTRAZENPullback in an uptrend

Buys a pause inside a rising trend.

BuyRSI(14) below 40, price above 200-day EMA
Sell8% profit, or after 30 days
Real prices · every charge countedRun on ASTRAZEN
Backtest idea · ASTRAZENBuy the dip

Buys after a sharp fall, betting on a bounce.

BuyRSI(14) drops below 30
Sell10% profit, or after 20 days
Real prices · every charge countedRun on ASTRAZEN
Backtest idea · ASTRAZEN52-week high breakout

Buys strength, when the price makes a new one-year high.

BuyCloses at a 52-week high
Sell8% stop loss
Real prices · every charge countedRun on ASTRAZEN
Backtest idea · ASTRAZENGolden cross

Follows the long trend: in when the fast average crosses above the slow one.

Buy50-day EMA crosses above 200-day
SellWhen it crosses back below
Real prices · every charge countedRun on ASTRAZEN
MACD momentum on ASTRAZENBuy when MACD crosses above signal, price above 200-day SMA
Lower band bounce on ASTRAZENBuy when closes below the lower Bollinger band
Supertrend rider on ASTRAZENBuy when supertrend turns up
Buy the dip on ASTRAZENBuy when RSI(14) drops below 30
52-week high breakout on ASTRAZENBuy when closes at a 52-week high

Peers side by sideCompanies in the same exchange-defined industry group, largest first. Tap a heading to sort.

Pharmaceuticals
CompanyWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.How many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.The share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.How much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.How much operating profit the company made on all the money in the business, whether it came from owners or lenders.Borrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.Of every ₹100 of sales, how much is left as profit after all costs, interest and tax.How much sales grew in the latest quarter against the same quarter a year earlier.The cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
SUNPHARMA
Sun Pharmaceutical Industries Limited
4.49 L cr41.0x5.0x14.7%19.1%0.0317.8%+11.9%0.85%
DIVISLAB
Divi's Laboratories Limited
2.93 L cr87.2x16.3x16.2%21.5%0.0027.6%+35.4%0.27%
TORNTPHARM
Torrent Pharmaceuticals Limited
1.75 L cr77.9x9.6x17.0%15.2%0.7612.1%+50.8%0.82%
LAURUSLABS
Laurus Labs Limited
1.25 L cr93.6x20.7x17.7%17.9%0.4017.0%+33.4%0.09%
ZYDUSLIFE
Zydus Lifesciences Limited
1.20 L cr28.9x4.3x18.3%19.9%0.4414.1%+29.2%0.08%
DRREDDY
Dr. Reddy's Laboratories Limited
1.17 L cr41.6x3.0x11.5%13.9%0.158.3%-1.5%0.57%
CIPLA
Cipla Limited
1.14 L cr39.5x3.2x11.7%16.0%0.0110.1%-2.4%0.92%
MANKIND
Mankind Pharma Limited
1.08 L cr48.3x6.2x12.4%12.9%0.3014.7%+17.3%0.00%
AUROPHARMA
Aurobindo Pharma Limited
1.03 L cr26.1x2.6x9.9%12.8%0.2110.8%+23.9%0.39%
LUPIN
Lupin Limited
90,173 cr17.3x3.8x26.9%28.8%0.2317.0%+11.1%0.91%
GLENMARK
Glenmark Pharmaceuticals Limited
74,679 cr51.5x6.7x14.1%20.4%0.089.2%-31.3%0.09%
ALKEM
Alkem Laboratories Limited
62,443 cr30.2x4.2x17.6%20.6%0.1213.4%+13.8%1.01%
BIOCON
Biocon Limited
58,987 cr215.4x1.7x1.1%3.0%0.411.9%+2.2%0.14%
ABBOTINDIA
Abbott India Limited
54,122 cr32.7x----23.0%+11.0%2.58%
GLAND
Gland Pharma Limited
53,307 cr43.1x5.0x10.5%15.0%0.0217.5%+23.3%0.62%
IPCALAB
IPCA Laboratories Limited
47,039 cr33.5x5.4x13.2%16.6%0.0614.2%+13.8%0.32%
GLAXO
GlaxoSmithKline Pharmaceuticals Limited
44,693 cr39.5x23.8x48.9%66.5%0.0027.6%+20.8%2.16%
EMCURE
Emcure Pharmaceuticals Limited
44,294 cr40.5x8.3x19.6%24.8%0.2710.7%+24.3%0.15%
AJANTPHARM
Ajanta Pharma Limited
40,909 cr32.4x8.4x25.4%32.7%0.0220.3%+32.5%0.98%
SAILIFE
Sai Life Sciences Limited
37,978 cr100.5x14.1x15.1%20.9%0.1715.9%+22.5%0.00%
WOCKPHARMA
Wockhardt Limited
32,931 cr80.3x6.4x4.0%6.5%0.3910.8%+23.9%0.00%
ACUTAAS
Acutaas Chemicals Limited
32,677 cr74.4x17.6x23.5%31.7%0.0027.5%+42.7%0.06%
PPLPHARMA
Piramal Pharma Limited
31,813 cr-3.9x-4.0%0.8%0.69-2.1%+28.1%0.00%
NEULANDLAB
Neuland Laboratories Limited
27,527 cr60.8x13.6x21.4%27.5%0.1719.6%-12.6%0.16%
RUBICON
Rubicon Research Limited
27,450 cr84.1x19.4x19.1%23.4%0.2815.5%+39.9%0.09%
APLLTD
Alembic Pharmaceuticals Limited
20,528 cr24.3x3.5x12.4%11.7%0.259.9%+36.3%1.15%
GRANULES
Granules India Limited
19,762 cr27.6x3.0x13.5%15.7%0.0912.1%+20.3%0.22%
ERIS
Eris Lifesciences Limited
18,530 cr26.0x4.5x18.1%13.9%0.5821.6%+12.6%0.54%
ONESOURCE
Onesource Specialty Pharma Limited
18,189 cr-3.1x-1.3%0.4%0.25-0.1%+37.4%0.00%
SHILPAMED
Shilpa Medicare Limited
17,902 cr53.6x6.5x9.8%11.4%0.2418.1%+43.0%0.07%
ALIVUS
Alivus Life Sciences Limited
17,737 cr26.5x4.9x18.4%24.6%0.0024.9%+16.0%0.35%
PFIZER
Pfizer Limited
17,575 cr20.4x4.0x17.2%23.4%0.0032.4%+13.2%1.95%
COHANCE
Cohance Lifesciences Limited
17,462 cr507.1x4.5x5.1%8.0%0.06-0.3%-14.2%0.00%
NATCOPHARM
Natco Pharma Limited
16,098 cr17.7x1.6x16.9%17.1%0.1126.9%-29.0%0.70%
CAPLIPOINT
Caplin Point Laboratories Limited
15,851 cr23.0x4.1x19.9%24.7%0.0029.4%+17.9%0.38%
ASTRAZEN
AstraZeneca Pharma India Limited
15,109 cr85.0x17.2x22.8%31.2%0.006.8%+30.4%0.60%
JUBLPHARMA
Jubilant Pharmova Limited
14,870 cr56.2x2.1x6.0%8.7%0.542.9%+20.5%0.54%
CORONA
CORONA Remedies Limited
13,799 cr66.7x17.1x24.8%27.8%0.1213.3%+22.2%0.44%
MARKSANS
Marksans Pharma Limited
13,349 cr23.8x4.0x25.4%35.1%0.0116.7%+30.5%0.31%
CONCORDBIO
Concord Biotech Limited
11,738 cr42.0x5.7x13.5%17.9%0.0023.9%+25.1%0.67%

Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.

Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.

Month by month
YearJanFebMarAprMayJunJulAugSepOctNovDecYear
2026
-5.3
+3.5
-12.2
+5.8
+5.1
-4.7
-1.5
-14.2
-11.0
+2.9
-4.0
·
-32.3%
11m
2025
-1.0
-7.4
+28.5
+0.8
-8.2
+11.8
+3.1
-7.9
+7.6
+4.9
-5.6
+0.1
+23.6%
2024
+19.7
-16.6
-3.4
+0.1
+15.8
+1.2
+12.6
-6.4
+21.0
-4.3
-13.9
+11.3
+32.2%
2023
+1.9
-0.5
-2.8
-2.0
+11.7
+4.1
+4.3
+10.2
+5.7
+3.8
+1.9
+16.0
+67.6%
2022
-9.7
-6.7
-2.2
+7.8
+9.4
-10.1
+13.3
+0.4
+1.2
+6.0
+2.3
-2.3
+6.4%
2021
-21.5
-5.2
-12.4
+29.9
-3.3
-4.4
-6.7
-7.8
-0.5
-2.7
+4.3
-1.2
-32.9%
2020
+2.1
-3.5
-6.8
+26.3
+0.6
+16.2
-5.9
+6.4
+21.2
-0.1
+5.5
+1.8
+76.6%
2019
+10.3
+26.6
-2.0
+18.6
-16.5
+8.1
-9.3
-2.6
+23.1
+17.8
-2.8
-1.2
+80.2%
2018
-2.6
-9.9
-9.4
+12.6
+14.0
+19.2
+7.8
+23.6
-17.3
+9.7
-18.8
+4.2
+24.4%
2017
+1.6
-3.2
+2.7
+4.0
-4.5
-1.6
+0.8
-2.0
+0.9
+15.2
+7.9
+2.9
+26.0%
Monthly movebelow -10%-10 to -5-5 to -2-2 to 00 to +2+2 to +5+5 to +10above +10%month in progress

Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.

Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.

DatePartySideQuantityPriceValue
2024-10-07GRAVITON RESEARCH CAPITAL LLP · bulkSELL1,25,166₹7,887.16₹98.72 Cr
2024-10-07GRAVITON RESEARCH CAPITAL LLP · bulkBUY1,25,166₹7,884.41₹98.69 Cr
2024-09-30GRAVITON RESEARCH CAPITAL LLP · bulkSELL1,27,119₹7,804.96₹99.22 Cr
2024-09-30GRAVITON RESEARCH CAPITAL LLP · bulkBUY1,27,119₹7,802.00₹99.18 Cr
2024-09-24GRAVITON RESEARCH CAPITAL LLP · bulkSELL1,31,308₹7,506.36₹98.56 Cr
2024-09-24GRAVITON RESEARCH CAPITAL LLP · bulkBUY1,31,308₹7,499.17₹98.47 Cr
2019-04-03ICICI PRUDENTIAL MUTUAL FUND A/C VOLATILITY ADVANTAGE PLAN · bulkSELL1,25,000₹2,000.00₹25.00 Cr

The last two years of the company's filings to the exchange, grouped by the exchange's own categories. Each opens the original document.

Read enough? Test ASTRAZEN. “Buy ASTRAZEN when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.

Run it free